53315
document
Comparison of cefuroxime axetil , cefaclor , and amoxicillin-clavulanate potassium suspensions in acute otitis media in infants and children . In this randomized , blinded , multicenter comparison study , 377 infants and children with acute otitis media ( AOM ) received a 10-day course of an oral suspension of one of the following : cefuroxime axetil ( CAE ) , 30 mg/kg/day ; cefaclor ( CEC ) , 40 mg/kg/day ; or amoxicillin-clavulanate potassium ( AMX-CL ) , 40 mg/kg/day . Clinical efficacy was determined by pneumatic otoscopy and tympanometric testing 3 to 5 , 11 to 14 , and 22 to 26 days after the initiation of therapy . There was a statistically significant difference among the three treatment groups with respect to clinical outcome ; more patients in the CAE group ( 62 % ) than in the CEC group ( 46 % ) or the AMX-CL group ( 52 % ) had complete resolution of signs and symptoms of AOM ( including effusion ) . Paired comparisons revealed a significant difference in efficacy between CAE and CEC and a nearly significant difference between AMX-CL and CEC . Taste acceptability was highest for CEC and lowest for this formulation of CAE . Significantly more patients in the AMX-CL group than in the CAE or CEC group had a side effect , primarily diarrhea , vomiting , or diaper rash . We conclude that CAE suspension has greater clinical efficacy than CEC and fewer side effects than AMX-CL .
53316
Intervention_Pharmacological
cefuroxime axetil
53317
Intervention_Pharmacological
amoxicillin-clavulanate potassium
53318
Intervention_Pharmacological
cefuroxime axetil ( CAE )
53319
Intervention_Pharmacological
cefaclor ( CEC )
53320
Intervention_Pharmacological
amoxicillin-clavulanate potassium ( AMX-CL )
53321
Intervention_Pharmacological
CAE
53322
Intervention_Pharmacological
AMX-CL
53323
Intervention_Pharmacological
CAE
53324
Intervention_Pharmacological
CEC
53325
Intervention_Pharmacological
AMX-CL
53326
Intervention_Pharmacological
CEC
53327
Intervention_Pharmacological
CEC
53328
Intervention_Pharmacological
CAE
53329
Intervention_Pharmacological
AMX-CL
53330
Intervention_Pharmacological
CAE
53331
Intervention_Pharmacological
CEC
53332
Intervention_Pharmacological
AMX-CL
53333
Outcome_Other
Clinical efficacy
53334
Outcome_Physical
signs and symptoms of AOM ( including effusion )
53335
Outcome_Physical
efficacy
53336
Outcome_Other
Taste acceptability
53337
Outcome_Adverse-effects
primarily diarrhea
53338
Outcome_Other
clinical efficacy
53339
Outcome_Adverse-effects
side effects
53340
Participant_Condition
acute otitis media
53341
Participant_Age
infants and children
53342
Participant_Sample-size
377
53343
Participant_Age
infants and children
53344
Participant_Condition
acute otitis media ( AOM )